The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...

Two months ago, Sanofi withdrew the only US-approved vaccine, dengvaxia, after cases of children dying in the Philippines ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

The Nifty Pharma index closed 0.1 per cent at 22661.25. Benchmark NSE Nifty50 index ended up 217.96 points at 24213.3, while the BSE Sensex stood 694.39 points at 79476.63. Among ...

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with ...

A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | ...

Dr Arshad Khanani shares insights, including data on anti-VEGF treatment and macular atrophy, fibrosis biomarkers, and PCV combination therapies.

Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.